Aviva PLC reduced its holdings in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 17.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 36,950 shares of the company’s stock after selling 7,752 shares during the period. Aviva PLC’s holdings in Bausch Health Companies were worth $256,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in the company. Wipfli Financial Advisors LLC purchased a new stake in shares of Bausch Health Companies in the 3rd quarter valued at $25,000. Quadrant Capital Group LLC boosted its position in shares of Bausch Health Companies by 420.1% in the 3rd quarter. Quadrant Capital Group LLC now owns 5,851 shares of the company’s stock valued at $40,000 after purchasing an additional 4,726 shares during the period. FMR LLC raised its stake in Bausch Health Companies by 58.3% during the 2nd quarter. FMR LLC now owns 10,057 shares of the company’s stock valued at $84,000 after acquiring an additional 3,703 shares during the last quarter. Assetmark Inc. raised its stake in Bausch Health Companies by 454.3% during the 2nd quarter. Assetmark Inc. now owns 10,421 shares of the company’s stock valued at $87,000 after acquiring an additional 8,541 shares during the last quarter. Finally, NewEdge Advisors LLC purchased a new position in shares of Bausch Health Companies during the 2nd quarter worth approximately $95,000. 66.99% of the stock is owned by institutional investors and hedge funds.
Bausch Health Companies Price Performance
Shares of NYSE:BHC opened at $9.31 on Wednesday. Bausch Health Companies Inc. has a one year low of $4.00 and a one year high of $24.30. The business’s fifty day moving average price is $7.74 and its two-hundred day moving average price is $7.17. The company has a debt-to-equity ratio of 78.21, a quick ratio of 0.80 and a current ratio of 1.08. The stock has a market cap of $3.37 billion, a PE ratio of -15.02, a price-to-earnings-growth ratio of 0.15 and a beta of 1.06.
Bausch Health Companies Profile
Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products.
Further Reading
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHC – Get Rating).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
